19 Einträge gefunden

1. Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy

   1. Rolles, Benjamin
   2. Gorgulho, Joao
   3. Tometten, Mareike
   4. Roderburg, Christoph
   5. Vieri, Margherita
   6. Abels, Anne
   7. Vucur, Mihael

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies

   1. Gorgulho, Joao
   2. Roderburg, Christoph
   3. Heymann, Felix
   4. Schulze-Hagen, Maximilian
   5. Beier, Fabian
   6. Vucur, Mihael
   7. Kather, Jakob N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AjET" Working Group of the German Society for Pediatric Oncology and Hematology

   1. Escherich, Gabriele
   2. Bielack, Stefan
   3. Maier, Stephan
   4. Braungart, Ralf
   5. Brümmendorf, Tim H
   6. Freund, Mathias
   7. Grosse, Regine

   2017 - Forschungsinformationssystem des UKE
4. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

   1. Cortes, Jorge E
   2. Gambacorti-Passerini, Carlo
   3. Kim, Dong-Wook
   4. Kantarjian, Hagop M
   5. Lipton, Jeff H
   6. Lahoti, Amit
   7. Talpaz, Moshe

   2017 - Forschungsinformationssystem des UKE
5. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

   1. Brümmendorf, Tim H
   2. Cortes, Jorge E
   3. Khoury, Hanna J
   4. Kantarjian, Hagop M
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Conlan, Maureen G

   2016 - Forschungsinformationssystem des UKE
6. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

   1. Cortes, Jorge E
   2. Khoury, Hanna J
   3. Kantarjian, Hagop M
   4. Lipton, Jeff H
   5. Kim, Dong-Wook
   6. Schafhausen, Philippe
   7. Matczak, Ewa

   2016 - Forschungsinformationssystem des UKE
7. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

   1. Cortes, Jorge E
   2. Jean Khoury, H
   3. Kantarjian, Hagop
   4. Brümmendorf, Tim H
   5. Mauro, Michael J
   6. Matczak, Ewa
   7. Pavlov, Dmitri

   2016 - Forschungsinformationssystem des UKE
8. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers

   1. Ummanni, Ramesh
   2. Duscharla, Divya
   3. Barett, Christine
   4. Venz, Simone
   5. Schlomm, Thorsten
   6. Heinzer, Hans
   7. Walther, Reinhard

   2015 - Forschungsinformationssystem des UKE
9. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial

   1. Brümmendorf, Tim H
   2. Cortes, Jorge E
   3. de Souza, Cármino Antonio
   4. Guilhot, Francois
   5. Duvillié, Ladan
   6. Pavlov, Dmitri
   7. Gogat, Karïn

   2015 - Forschungsinformationssystem des UKE
10. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

    1. Gambacorti-Passerini, Carlo
    2. Kantarjian, Hagop M
    3. Kim, Dong-Wook
    4. Khoury, Hanna J
    5. Turkina, Anna G
    6. Brümmendorf, Tim H
    7. Matczak, Ewa

    2015 - Forschungsinformationssystem des UKE
11. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

    1. Shah, Neil P
    2. Guilhot, François
    3. Cortes, Jorge E
    4. Schiffer, Charles A
    5. le Coutre, Philipp
    6. Brümmendorf, Tim H
    7. Kantarjian, Hagop M

    2014 - Forschungsinformationssystem des UKE
12. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

    1. Kantarjian, Hagop M
    2. Cortes, Jorge E
    3. Kim, Dong-Wook
    4. Khoury, H Jean
    5. Brümmendorf, Tim H
    6. Porkka, Kimmo
    7. Martinelli, Giovanni

    2014 - Forschungsinformationssystem des UKE
13. Bosutinib: a novel second-generation tyrosine kinase inhibitor

    1. Isfort, Susanne
    2. Amsberg, Gunhild
    3. Schafhausen, Philippe
    4. Koschmieder, Steffen
    5. Brümmendorf, Tim H

    2014 - Forschungsinformationssystem des UKE
14. Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines

    1. Honecker, Friedemann
    2. Rohlfing, Tina
    3. Harder, Sönke
    4. Braig, Melanie
    5. Gillis, Ad J M
    6. Gläsener, Stephanie
    7. Barett, Christine

    2014 - Forschungsinformationssystem des UKE
15. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

    1. Gambacorti-Passerini, Carlo
    2. Brümmendorf, Tim H
    3. Kim, Dong-Wook
    4. Turkina, Anna G
    5. Masszi, Tamas
    6. Assouline, Sarit
    7. Durrant, Simon

    2014 - Forschungsinformationssystem des UKE
16. Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors

    1. Balabanov, Stefan
    2. Wilhelm, Thomas
    3. Venz, Simone
    4. Amsberg, Gunhild
    5. Scharf, Christian
    6. Pospisil, Heike
    7. Balabanov, Melanie

    2013 - Forschungsinformationssystem des UKE - frei zugänglich
17. A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma

    1. Wege, Henning
    2. Brümmendorf, Tim H
    3. Gambacorti-Passerini, Carlo

    2013 - Forschungsinformationssystem des UKE
18. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.

    1. Ziegler, Patrick
    2. Schrezenmeier, Hubert
    3. Akkad, Jamil
    4. Brassat, Ute
    5. Vankann, Lucia
    6. Panse, Jens
    7. Wilop, Stefan

    2012 - Forschungsinformationssystem des UKE
19. Forced activation of β-catenin signaling supports the transformation of hTERT-immortalized human fetal hepatocytes.

    1. Wege, Henning
    2. Heim, Denise
    3. Lütgehetmann, Marc
    4. Dierlamm, Judith
    5. Lohse, Ansgar W.
    6. Brümmendorf, Tim H

    2011 - Forschungsinformationssystem des UKE